Compare · RVTY vs TLIS
RVTY vs TLIS
Side-by-side comparison of Revvity Inc. (RVTY) and Talis Biomedical Corporation (TLIS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both RVTY and TLIS operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- RVTY carries a market cap of $17.24B.
- RVTY has hit the wire 9 times in the past 4 weeks while TLIS has been quiet.
- RVTY has more recent analyst coverage (24 ratings vs 5 for TLIS).
- Company
- Revvity Inc.
- Talis Biomedical Corporation
- Price
- -
- -
- Market cap
- $17.24B
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 9
- 0
- Recent ratings
- 24
- 5
Talis Biomedical Corporation
Talis Biomedical Corporation operates as a molecular diagnostic company. It is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. The company is also developing Talis One assay kits for respiratory infections, infections related to women's health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A and influenza B plus SARS-CoV-2. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Menlo Park, California.
Latest RVTY
- vVardis Raises $175 Million Ahead of NYSE IPO: NYSE Content Update
- Revvity Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Revvity to Showcase Strategy for Powering Scientific Intelligence at 2026 Investor Day
- SEC Form 10-Q filed by Revvity Inc.
- Revvity upgraded by CFRA
- Revvity Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
- Revvity Announces Financial Results for the Third Quarter of 2026
- Revvity Board Declares Quarterly Dividend
- Revvity Launches Signals LabGistics Solution to Connect and Orchestrate Scientific Workflows
- Revvity to Present at Upcoming Investor Conferences
Latest TLIS
- Amendment: SEC Form SC 13D/A filed by Talis Biomedical Corporation
- SEC Form 15-12G filed by Talis Biomedical Corporation
- SEC Form 25-NSE filed by Talis Biomedical Corporation
- Talis Biomedical Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- SEC Form S-8 POS filed by Talis Biomedical Corporation
- SEC Form S-8 POS filed by Talis Biomedical Corporation
- SEC Form S-8 POS filed by Talis Biomedical Corporation
- SEC Form S-8 POS filed by Talis Biomedical Corporation
- Large owner Leonard Braden Michael bought $44,240 worth of shares (30,100 units at $1.47) (SEC Form 4)
- Talis Biomedical Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits